Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients

被引:0
作者
Sirken, G.
Raja, R.
Rizkala, A. R.
机构
[1] Langhorne Nephrol, Langhorne, PA 19147 USA
[2] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
[3] Watson Labs Inc, Morristown, NJ USA
关键词
bacteremia; ferric gluconate; hemodialysis; infection rates; iron sucrose;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: In vitro evidence suggests that different intravenous iron (i.v. Fe) preparations may be associated with different infection rates. This observational study was to determine if different bacteremia rates are associated with different types or amounts of i.v. Fe preparations. Materials and Methods: This retrospective, single-center study was carried out from April 2001 - November 2002, a period in which a global switch from ferric gluconate (FG) to iron sucrose (IS) occurred. During Period I (April 2001 - January 2002) FG was the only i.v. Fe administered in our hemodialysis unit. During Period 11 (February 2002 - November 2002) IS was the only i.v. Fe administered in our unit. Group A (n = 63) received hemodialysis during both Period I and Period II. Group B (n = 4 1) received hemodialysis either during Period I or Period II. Results: More bacteremic episodes occurred while IS than while FG was being administered. The adjusted bacteremia incidence rate ratios (IRRs) associated with use of IS vs. FG were 2.92 (95% CI, 1.01-8.5) and 2.84 (95% CI 1.32-6.09) in Groups A and B, respectively. The adjusted bacteremia IRRs associated with receiving > 2,000 mg of i.v. Fe were 2.42 (95% CI 1.03-5.6) and 1.54 (95% CI 0.43-5.69) in Groups A and 13, respectively. Use of catheters as hemodialysis access increased bacteremia risk in both groups. Conclusions: Use of iron sucrose is associated with higher bacteremia rates than ferric gluconate. The potential association between the cumulative amount of i.v. Fe administered and bacteremia risk is unclear. Randomized clinical trials are needed to verify our findings.
引用
收藏
页码:348 / 356
页数:9
相关论文
共 25 条
  • [11] Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy
    Eschbach, JW
    Adamson, JW
    [J]. KIDNEY INTERNATIONAL, 1999, 55 : S35 - S43
  • [12] HENDERSON PA, 1969, BLOOD-J HEMATOL, V34, P357
  • [13] Hoen B, 1998, J AM SOC NEPHROL, V9, P869
  • [14] Hoen B, 2002, CLIN NEPHROL, V57, P457
  • [15] Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population
    Kalantar-Zadeh, K
    Kopple, JD
    Kilpatrick, RD
    McAllister, CJ
    Shinaberger, CS
    Gjertson, DW
    Greenland, S
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (03) : 489 - 500
  • [16] Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients
    Kalantar-Zadeh, K
    Rodriguez, RA
    Humphreys, MH
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (01) : 141 - 149
  • [17] Nurmohamed SA, 2005, NETH J MED, V63, P376
  • [18] Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration
    Parkkinen, J
    von Bonsdorff, L
    Peltonen, S
    Grönhagen-Riska, C
    Rosenlöf, K
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (11) : 1827 - 1834
  • [19] SANTOS JI, 1994, INFECT DIS CLIN N AM, V8, P243
  • [20] SCHWAB R, 1989, SEMIN ONCOL, V16, P20